0001415889-24-027709.txt : 20241126 0001415889-24-027709.hdr.sgml : 20241126 20241126161507 ACCESSION NUMBER: 0001415889-24-027709 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241122 FILED AS OF DATE: 20241126 DATE AS OF CHANGE: 20241126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Manning Paul B CENTRAL INDEX KEY: 0001494695 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38529 FILM NUMBER: 241503947 MAIL ADDRESS: STREET 1: 200 GARRETT STREET SUITE S CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001660334 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 463137900 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-453-3300 MAIL ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 4 1 form4-11262024_041101.xml X0508 4 2024-11-22 0001660334 Verrica Pharmaceuticals Inc. VRCA 0001494695 Manning Paul B 200 GARRETT STREET, SUITE S CHARLOTTESVILLE VA 22902 true false true false 0 Common Stock 2024-11-22 4 P 0 18426966 A 26278094 D Common Stock 2024-11-22 4 P 0 4494382 A 5976101 I See footnote Common Stock 2024-11-26 4 G 0 450000 0 D 25828094 D Common Stock 891870.41 I By trust Common Stock 891870.42 I By trust Common Stock 891870.42 I By trust Common Stock 3324338.75 I By trust Common Stock 256634 I See footnote Series A Warrants (right to buy) 1.0680 2024-11-22 4 P 0 9213483 A 2024-11-22 2025-11-22 Common Stock 9213483 9213483 D Series B Warrants (right to buy) 1.3350 2024-11-22 4 P 0 9213483 A 2024-11-22 2029-11-22 Common Stock 9213483 9213483 D Series A Warrants (right to buy) 1.0680 2024-11-22 4 P 0 2247191 A 2024-11-22 2025-11-22 Common Stock 2247191 2247191 I See footnote Series B Warrants (right to buy) 1.3350 2024-11-22 4 P 0 2247191 A 2024-11-22 2029-11-22 Common Stock 2247191 2247191 I See footnote The reported securities are included within 18,426,966 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock,a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. The shares are held by Mr. Manning jointly with his spouse. The reported securities are included within 4,494,382 investment units purchased by BKB Growth Investments, LLC ("BKB") for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, one Series A warrant and one Series B warrant, each to purchase up to 2,247,191 shares of common stock. The shares are held directly by BKB. The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person's spouse is trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The shares are held directly by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI. /s/ Mark Ballantyne, Attorney-in-Fact 2024-11-26